Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.
about
The complexity of growth failure in children receiving tyrosine kinase inhibitor therapy for chronic myelogenous leukemia.Helping children with growth failure due to tyrosine kinase inhibitor drugs requires knowledge of the pathogenesis of the problem.Pharmacology and pharmacokinetics of imatinib in pediatric patients.T-cell-rich HLA-haploidentical hematopoietic stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia without posttransplant tyrosine kinase inhibitor therapy.
P2860
Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Recognizing Endocrinopathies A ...... Chronic Myelogenous Leukemia.
@en
type
label
Recognizing Endocrinopathies A ...... Chronic Myelogenous Leukemia.
@en
prefLabel
Recognizing Endocrinopathies A ...... Chronic Myelogenous Leukemia.
@en
P2093
P2860
P356
P1476
Recognizing Endocrinopathies A ...... Chronic Myelogenous Leukemia.
@en
P2093
Donald Zimmerman
Jill Samis
Meinolf Suttorp
Nobuko Hijiya
Robert J Arceci
P2860
P304
P356
10.1002/PBC.26028
P577
2016-04-21T00:00:00Z